Primer: Edge Medical (2675 HK) - Aug 2026
Edge Medical is a high-growth, pre-profitability surgical robotics company poised to capture significant share in the rapidly expanding Chinese...
97 Views
APAC Healthcare Weekly (August 23) – Henlius Bio, Wuxi XDC, Chugai Pharma, Daiichi Sankyo, Celltrion
Henlius strikes biosimilar commercialization deal with Sandoz. Chugai signs exclusive license deal with GSK for anti-dengue virus antibody....
100 Views
Shenzhen Edge Medical (精锋医疗) IPO Trading
Shenzhen Edge Medical raises $154m in global offering. We provide an update on the deal upon its listing on Jan 8th, 2026.
337 Views
Pre-IPO Shenzhen Edge Medical (PHIP Updates) - Some Points Worth the Attention
Edge's dual product line faces commercialization challenge, with focus on increasing repurchase rate of consumables to drive profit. HK$43.24 IPO...
452 Views
Edge Medical IPO: Product Mix and Pipeline Will Support Growth Momentum and Justify Valuation
Edge Medical launches Hong Kong IPO to raise up to HK$1,198M, selling 27.7M shares at HK$43.24. Specializes in advanced surgical robots, poised...
696 Views